Nagrestipen
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis[1].
Product Specifications
CAS Number
166089-33-4
UNSPSC
12352209
Target
Drug Derivative
Type
Peptides
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nagrestipen.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(NCC(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@H]4C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC5=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N6[C@@H](CCC6)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC9=CC=C(C=C9)O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC4=O)C(N[C@@H](CC%10=CC=CC=C%10)C(N[C@@H](CO)C(N[C@@H](CC%11=CC=C(C=C%11)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N%12[C@@H](CCC%12)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC%13=CC=CC=C%13)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CC%14=CC=C(C=C%14)O)C(N[C@@H](CC%15=CC=CC=C%15)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@H]5CCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N
Molecular Formula
C338H516N88O108S4
Molecular Weight
7668.48
References & Citations
[1]Kenshiro Shiraishi, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res. 2008 Feb 15;14 (4) :1159-66.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1194249-01 0.02 mg (E-Coli)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details MBS1194249-02 0.1 mg (E-Coli)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details MBS1194249-03 0.02 mg (Yeast)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details MBS1194249-04 0.1 mg (Yeast)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details MBS1194249-05 0.02 mg (Baculovirus)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details MBS1194249-06 0.02 mg (Mammalian-Cell)
Recombinant Clostridium phytofermentans Urease accessory protein UreG (ureG)
Sign In for Pricing
View Details